- Home
- PYXS vs TELA Comparison
PYXS vs TELA Comparison
Compare PYXS & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- TELA
- Stock Information
- Founded
- PYXS 2018
- TELA 2012
- Country
- PYXS United States
- TELA United States
- Employees
- PYXS N/A
- TELA N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- TELA Medical/Dental Instruments
- Sector
- PYXS Health Care
- TELA Health Care
- Exchange
- PYXS Nasdaq
- TELA Nasdaq
- Market Cap
- PYXS 101.1M
- TELA 104.0M
- IPO Year
- PYXS 2021
- TELA 2019
- Fundamental
- Price
- PYXS $1.54
- TELA $2.70
- Analyst Decision
- PYXS Strong Buy
- TELA Strong Buy
- Analyst Count
- PYXS 7
- TELA 4
- Target Price
- PYXS $9.00
- TELA $9.25
- AVG Volume (30 Days)
- PYXS 543.0K
- TELA 167.6K
- Earning Date
- PYXS 03-20-2025
- TELA 03-20-2025
- Dividend Yield
- PYXS N/A
- TELA N/A
- EPS Growth
- PYXS N/A
- TELA N/A
- EPS
- PYXS N/A
- TELA N/A
- Revenue
- PYXS $16,146,000.00
- TELA $68,649,000.00
- Revenue This Year
- PYXS N/A
- TELA $30.39
- Revenue Next Year
- PYXS N/A
- TELA $25.51
- P/E Ratio
- PYXS N/A
- TELA N/A
- Revenue Growth
- PYXS N/A
- TELA 29.34
- 52 Week Low
- PYXS $1.39
- TELA $2.30
- 52 Week High
- PYXS $6.85
- TELA $7.52
- Technical
- Relative Strength Index (RSI)
- PYXS 43.02
- TELA 48.25
- Support Level
- PYXS $1.50
- TELA $2.56
- Resistance Level
- PYXS $1.67
- TELA $2.87
- Average True Range (ATR)
- PYXS 0.09
- TELA 0.17
- MACD
- PYXS 0.02
- TELA 0.01
- Stochastic Oscillator
- PYXS 53.57
- TELA 56.76
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About TELA TELA Bio Inc.
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.